Daniel Barber Sells 8,257 Shares of Aquestive Therapeutics (NASDAQ:AQST) Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) CEO Daniel Barber sold 8,257 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $4.29, for a total transaction of $35,422.53. Following the sale, the chief executive officer directly owned 660,574 shares of the company’s stock, valued at approximately $2,833,862.46. This represents a 1.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Barber also recently made the following trade(s):

• On Tuesday, March 10th, Daniel Barber sold 180,677 shares of Aquestive Therapeutics stock. The stock was sold at an average price of $4.17, for a total transaction of $753,423.09.

Aquestive Therapeutics Trading Down 1.2%

NASDAQ AQST opened at $4.09 on Wednesday. The company has a fifty day simple moving average of $4.15 and a 200 day simple moving average of $4.73. The company has a market cap of $513.09 million, a P/E ratio of -6.70 and a beta of 1.50. Aquestive Therapeutics, Inc. has a 1 year low of $2.22 and a 1 year high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.07. The firm had revenue of $14.45 million for the quarter, compared to the consensus estimate of $10.90 million. Equities research analysts forecast that Aquestive Therapeutics, Inc. will post -0.43 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on AQST shares. Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Oppenheimer started coverage on shares of Aquestive Therapeutics in a research note on Friday, April 24th. They set an “outperform” rating and a $8.00 target price for the company. Lake Street Capital set a $6.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, February 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $8.80.

Hedge Funds Weigh In On Aquestive Therapeutics

Several large investors have recently bought and sold shares of AQST. Aberdeen Group plc acquired a new position in shares of Aquestive Therapeutics in the 3rd quarter valued at $3,494,000. Blue Owl Capital Holdings LP raised its stake in shares of Aquestive Therapeutics by 35.9% in the 3rd quarter. Blue Owl Capital Holdings LP now owns 1,250,000 shares of the company’s stock valued at $6,988,000 after buying an additional 330,000 shares in the last quarter. Federated Hermes Inc. acquired a new position in shares of Aquestive Therapeutics in the 3rd quarter valued at $4,381,000. AXQ Capital LP acquired a new position in shares of Aquestive Therapeutics in the 3rd quarter valued at $387,000. Finally, Verus Capital Partners LLC acquired a new position in shares of Aquestive Therapeutics in the 3rd quarter valued at $188,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.